Compare SHASUN PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA AUROBINDO PHARMA SHASUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 123.9 11.4 1,084.4% View Chart
P/BV x 8.5 2.1 404.3% View Chart
Dividend Yield % 0.2 0.5 46.7%  

Financials

 SHASUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
AUROBINDO PHARMA
Mar-19
SHASUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs94830 11.3%   
Low Rs46527 8.7%   
Sales per share (Unadj.) Rs214.2333.9 64.1%  
Earnings per share (Unadj.) Rs5.340.4 13.2%  
Cash flow per share (Unadj.) Rs15.851.8 30.6%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %1.40.4 388.3%  
Book value per share (Unadj.) Rs53.3237.1 22.5%  
Shares outstanding (eoy) m56.62585.91 9.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.0 16.1%   
Avg P/E ratio x13.116.8 77.9%  
P/CF ratio (eoy) x4.413.1 33.7%  
Price / Book Value ratio x1.32.9 45.8%  
Dividend payout %18.76.2 302.5%   
Avg Mkt Cap Rs m3,958397,569 1.0%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m2,16425,849 8.4%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m12,127195,636 6.2%  
Other income Rs m2291,553 14.8%   
Total revenues Rs m12,356197,189 6.3%   
Gross profit Rs m1,00939,519 2.6%  
Depreciation Rs m5946,680 8.9%   
Interest Rs m4152,626 15.8%   
Profit before tax Rs m23031,767 0.7%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m-737,269 -1.0%   
Profit after tax Rs m30223,645 1.3%  
Gross profit margin %8.320.2 41.2%  
Effective tax rate %-31.722.9 -138.4%   
Net profit margin %2.512.1 20.6%  
BALANCE SHEET DATA
Current assets Rs m6,884153,645 4.5%   
Current liabilities Rs m8,456120,429 7.0%   
Net working cap to sales %-13.017.0 -76.3%  
Current ratio x0.81.3 63.8%  
Inventory Days Days62135 45.6%  
Debtors Days Days10864 168.9%  
Net fixed assets Rs m4,970103,909 4.8%   
Share capital Rs m113586 19.3%   
"Free" reserves Rs m2,875138,322 2.1%   
Net worth Rs m3,020138,908 2.2%   
Long term debt Rs m1,8171,800 101.0%   
Total assets Rs m13,347264,544 5.0%  
Interest coverage x1.613.1 11.9%   
Debt to equity ratio x0.60 4,645.0%  
Sales to assets ratio x0.90.7 122.9%   
Return on assets %5.49.9 54.1%  
Return on equity %10.017.0 58.8%  
Return on capital %13.323.8 55.9%  
Exports to sales %46.449.6 93.4%   
Imports to sales %14.218.8 75.9%   
Exports (fob) Rs m5,62297,091 5.8%   
Imports (cif) Rs m1,72836,741 4.7%   
Fx inflow Rs m5,84397,316 6.0%   
Fx outflow Rs m2,17340,589 5.4%   
Net fx Rs m3,66956,727 6.5%   
CASH FLOW
From Operations Rs m39816,220 2.5%  
From Investments Rs m-1,635-28,768 5.7%  
From Financial Activity Rs m1,30919,191 6.8%  
Net Cashflow Rs m716,656 1.1%  

Share Holding

Indian Promoters % 39.2 54.1 72.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 8.0 45.3%  
FIIs % 17.6 27.7 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.2 388.2%  
Shareholders   20,750 69,601 29.8%  
Pledged promoter(s) holding % 12.3 8.6 143.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   UNICHEM LAB  VENUS REMEDIES  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Buzz on the Street: A Look at Stocks, Sectors and the Economy(Podcast)

The stock markets in India remained rangebound this week. Economic data releases and third quarter results announcements were the focus of the week.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

How to Buy the Best Safe Stocks in 2020(The 5 Minute Wrapup)

Jan 17, 2020

Don't fall for the safe stocks narrative going around in the stock market these days.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market(Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS